Institut National De La Sante Et De La Recherche Medicale

Université Paris Diderot-Paris 7

Université Paris-Saclay

Acticor Biotech

Universite Paris-Xiii

Millennium Pharmaceuticals Limited

Université De Paris

Universite Paris Cité

Institut National De La Sante Et De La Recherche Medicale (Inserm)

Université Paris Diderot

Universite Paris Xiii Paris-Nord

Martine Jandrot-Perrus

Davinder Gill

Didier Letourneur

Samantha J Busfield

Philippe Billiald

Julien Muzard

Stéphane Loyau

Gillian A Kingsbury

Jean-Luc Villeval

Ming Diana Qian

Frederic Chaubet

Jean-Baptiste Michel

Alain Meulemans

Dominique Le Guludec

Laurent Feldman

Murielle Maire

Samatha J Busfield

William Vainchencker

Gilles Avenard

Benoit Ho-Tin-Noe

Laure Sarda

Jean-Luc Villelal

Davinder Singh Gill

The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.

Inhibition of platelet aggregation using anti-human GPVI antibodies

The present invention relates to humanized anti-human GPVI antibodies and uses thereof.

Anti-human GPVI antibodies and uses thereof

The invention relates to a vector targeting thrombus, having t-PA binding property consisting of a thrombus targeting fucoidan moiety, which is covalently linked to one or more t-PA binding amino groups by the reducing end of the said fucoidan moiety.

Aminofucoidan as a vector for fibrinolysis in thrombotic diseases

The present invention relates to a single chain variable fragment (scFv 9O12.2) directed against human glycoprotein VI, constituted of the VH and VL domains of 9 O12.2.2 monoclonal antibody linked via a (GlySer)peptide and followed by a 'c-myc' flag, represented by SEQ ID NO:1. The invention also concerns functional variants of said scFv 9O12.2 fragment with identical heavy and light chains complementary determining regions 1, 2 and 3, and preferably humanized functional variants such as the humanized scFv fragments represented by SEQ ID NO:28 or SEQ ID NO:47. The invention also relates to nucleic acids encoding such a scFv fragment, expression vectors and host cells to produce such a scFv fragment, as well as therapeutic uses of such a scFv fragment.

Anti-glycoprotein VI scFv fragment for treatment of thrombosis

The invention relates to methods and kits for determining platelet susceptibility to activation in a patient. More particularly, the present invention relates to a method for determining platelet susceptibility to activation in a patient, comprising a step consisting of measuring the level of GPVI dimers at the platelet surface in a blood sample obtained from said patient.

Method and kits for determining platelet susceptibility to activation in a patient

The present invention relates to diagnostic imaging and in particular to the diagnostic imaging of fibrosis. More particularly, the present invention provides a polypeptides, cyclic polypeptides and pharmaceutical compositions suitable for the non-invasive visualization of fibrosis. The polypeptide of the invention may comprise an amino acid sequence consisting of: X1-X2-M-H-G-L-X7-L-X9-X10-D-E (SEQ ID NO: 1) wherein amino acid X1 is R, F or P; amino acid X2 is F or V; amino acid X7 is Q, H or L; amino acid X9 is W or G and amino acid X10 is A or D.

Polypeptides, cyclic polypeptides and pharmaceutical comprising thereof for non invasive specific imaging of fibrosis

The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein V1, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the exposure vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

Glycoprotein VI antibodies and uses thereof

Growing community of inventors

Vanves, France

Martine Jandrot-Perrus